Bergen Addiction Research group, Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Subst Abuse Treat Prev Policy. 2021 Feb 27;16(1):20. doi: 10.1186/s13011-021-00354-1.
There is high co-occurrence of substance use disorders (SUD) and mental health disorders. We aimed to assess impact of substance use patterns and sociodemographic factors on mental health distress using the ten-item Hopkins Symptom Checklist (SCL-10) over time.
Nested prospective cohort study of 707 participants with severe SUD across nine opioid-agonist-therapy outpatient clinics and low-threshold municipality clinics in Norway, during 2017-2020. Descriptive statistics were derived at baseline and reported by means and standard deviation (SD). A linear mixed model analysis was used to assess the impact of substance use patterns and sociodemographic factors on SCL-10 sum score with beta coefficients with 95% confidence intervals (CI).
Mean (SD) SCL-10 score was 2.2 (0.8) at baseline with large variations across patients. We observed more symptoms of mental health disorders among people with frequent use of benzodiazepines (beta 3.6, CI:2.4;4.8), cannabis (1.3, CI:0.2;2.5), opioids (2.7, CI:1.1;4.2), and less symptoms among people using frequent stimulant use (- 2.7, CI:-4.1;-1.4) compared to no or less frequent use. Females (1.8, CI:0.7;3.0) and participants with debt worries (2.2, CI:1.1;3.3) and unstable living conditions (1.7, CI:0.0;3.3) had also higher burden of mental health symptoms. There were large individual variations in SCL-10 score from baseline to follow-up, but no consistent time trends indicating change over time for the whole group. 65% of the cohort had a mean score > 1.85, the standard reference score.
People with SUD have a considerable burden of mental health symptoms. We found no association between substance use patterns and change in mental health symptoms over time. This could suggest that the differences observed were indicating flattening of effects or self-medication to a larger degree than medication-related decline in mental health. This call for better individualized mental health assessment and patient care.
物质使用障碍(SUD)和精神健康障碍的并发率很高。我们旨在通过使用 10 项 Hopkins 症状清单(SCL-10)随时间评估物质使用模式和社会人口因素对心理健康困扰的影响。
这是一项嵌套的前瞻性队列研究,共纳入了 707 名来自挪威 9 家阿片类激动剂治疗门诊和低门槛市诊所的严重 SUD 患者,研究时间为 2017 年至 2020 年。基线时采用描述性统计,采用均值和标准差(SD)报告。采用线性混合模型分析评估物质使用模式和社会人口因素对 SCL-10 总分的影响,采用 beta 系数和 95%置信区间(CI)表示。
基线时的平均(SD)SCL-10 得分为 2.2(0.8),患者之间差异较大。我们观察到,与不频繁或很少使用相比,频繁使用苯二氮䓬类药物(β 3.6,CI:2.4;4.8)、大麻(1.3,CI:0.2;2.5)、阿片类药物(2.7,CI:1.1;4.2)的患者有更多的心理健康障碍症状,而频繁使用兴奋剂的患者则有较少的症状(-2.7,CI:-4.1;-1.4)。与不频繁或很少使用相比,女性(1.8,CI:0.7;3.0)、有债务担忧(2.2,CI:1.1;3.3)和不稳定生活条件(1.7,CI:0.0;3.3)的患者也有更高的心理健康症状负担。从基线到随访,SCL-10 评分存在较大的个体差异,但没有一致的时间趋势表明整个组随时间的变化。65%的队列平均得分>1.85,即标准参考得分。
患有 SUD 的人有相当大的心理健康症状负担。我们没有发现物质使用模式与随时间变化的心理健康症状之间的关联。这可能表明,观察到的差异表明影响程度趋于平稳,或者更多地是自我治疗,而不是与药物相关的心理健康恶化。这需要更好的个体化心理健康评估和患者护理。